Retatrutide, developed by Soma Corp., is receiving considerable attention as a innovative therapy for obesity control . This unique drug integrates the activity of a GLP-1 receptor agonist and a GIP receptor stimulant, designed to simply promote reduced body fat but also target associated metabolic conditions . Preliminary clinical studies have sho